Arndt Vogel shares news from EASL 2O24
Arndt Vogel shared the following posts from EASL 2O24 on X:
“Liver transplantation following HCC downstaging with atezolizumab/bevacizumab: preliminary results of the ImmunoXXL study:
- still early, but amazing data
- ICI before LTx seems feasible and safe
- A real chance to improve outcome in HCC.”
“Outcome of patients with HCC who achieved a complete response to ICI-based therapy:
- RWD, 174/3933 pts
- mRFS 30 months, 3 years OS 87%
- Great to report recurrence-free survival (!) after systemic therapy in advanced HCC.”
Arndt Vogel, MD, is a Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. Leading the GI-Cancer Center and the Center for Personalized Medicine, his research focuses on translational and clinical studies in gastrointestinal cancer. He’s actively engaged in various societies including ESMO, ASCO, and EASL. Additionally, he chairs the Hepatobiliary Cancer Study Group of the AIO, contributing significantly to clinical oncology in Germany. Within ESMO, he serves on the Guidelines Steering Committee.
